[Skip to Content]

Quiz

Clinical Pharmacy and Pharmacology

Painful Eruptions in a Patient With Cholangiocarcinoma Treated With Fibroblast Growth Factor Receptor Inhibitor

Educational Objective
Based on this clinical scenario and the accompanying image, understand how to arrive at a correct diagnosis.

1 Credit CME

JAMA Oncology

Published Online: October 28, 2021

JAMA Oncology Clinical Challenge

Article Information and Disclosures

Natasha S. Wylie, DNP, APRN¹;

Olayemi Sokumbi, MD²;

Jason S. Starr, DO¹

Author Affiliations

¹Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida
²Department of Dermatology, Mayo Clinic, Jacksonville, Florida

Read article on JAMA Network

Read Case Take Quiz Answer

A 65-year-old woman with locally advanced, unresectable intrahepatic cholangiocarcinoma being treated with pemigatinib, a fibroblast growth factor receptor inhibitor (FGFRi), presented with a painful eruption on the bilateral lower extremities. Pemigatinib treatment was initiated 2 months prior to the skin findings. Laboratory evaluation demonstrated a mildly elevated D-dimer level at 578 ng/mL fibrinogen-equivalent units, prolonged prothrombin time of 12.7 seconds, elevated phosphorus level at 6.8 mg/dL (of note, phosphorus was 3.1 mg/dL 1 month prior), and normal calcium level and kidney function. Other laboratory tests to note include cryoglobulin and cryofibrinogen, which both had negative results. Within weeks, there was rapid progression with skin necrosis despite treatment initiation with rivaroxaban. Physical examination revealed retiform purpura with areas of necrosis involving the bilateral lower extremities (Figure, A and B). A punch biopsy specimen from the right calf was obtained for histopathologic analysis (Figure, C and D).

Take Quiz

Please finish quiz first before checking answer.

B. Calciphylaxis

Cholangiocarcinoma is a rare malignant neoplasm that arises from intrahepatic and/or extrahepatic bile ducts. Treatment options include targeted systemic therapy, localized radiation therapy, and surgery. Treatments are based on tumor stage and location within the biliary tract. Standard-of-care first-line therapy for either locally advanced or metastatic cholangiocarcinoma is gemcitabine and cisplatin.¹ In the era of next-generation sequencing, targetable alterations have been identified in cholangiocarcinoma. One such alteration is FGFR2 fusions, which is identified in 15% of patients with intrahepatic cholangiocarcinoma.²^,3 In April 2020, the US Food and Drug Administration granted accelerated approval for pemigatinib, an oral inhibitor of FGFR1, FGFR2, and FGFR3. Common adverse effects affecting more than 30% of patients receiving oral therapy include alopecia, dysgeusia, diarrhea, and fatigue.⁴ Overall, the most common adverse effect of pemigatinib is hyperphosphatemia, which develops in approximately 60% of patients.²

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Corresponding Author: Natasha S. Wylie, DNP, APRN, Division of Hematology and Medical Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224 (wylie.natasha@mayo.edu).

Published Online: October 28, 2021. doi:10.1001/jamaoncol.2021.5578

Conflict of Interest Disclosures: Dr Starr reported receiving honoraria for consulting from Natera, Pfizer, TerSera Therapeutics, Ipsen, and Advanced Accelerator Applications outside the submitted work. No other disclosures were reported.

Additional Contributions: We thank the patient for granting permission to publish this information.

References

Valle J , Wasan H , Palmer DH , et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-1281. doi:10.1056/NEJMoa0908721 PubMed Google Scholar Crossref

Abou-Alfa GK , Sahai V , Hollebecque A , et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671-684. doi:10.1016/S1470-2045(20)30109-1 PubMed Google Scholar Crossref

Ross JS , Wang K , Gay L , et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19(3):235-242. doi:10.1634/theoncologist.2013-0352 PubMed Google Scholar Crossref

Pemazyre (pemigatinib). Package insert. Incyte Corporation; 2020.

Nigwekar SU , Thadhani R , Brandenburg VM . Calciphylaxis. N Engl J Med. 2018;378(18):1704-1714. doi:10.1056/NEJMra1505292 PubMed Google Scholar Crossref

Macklis P , Chung C , Kaffenberger B . Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib. JAAD Case Rep. 2020;7:125-127. doi:10.1016/j.jdcr.2020.11.022 PubMed Google Scholar Crossref

Lacouture ME , Sibaud V , Anadkat MJ , et al. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist. 2021;26(2):e316-e326. doi:10.1002/onco.13552 PubMed Google Scholar Crossref

Arudra K , Patel R , Tetzlaff MT , et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018;45(10):786-790. doi:10.1111/cup.13319 PubMed Google Scholar Crossref

McCarthy JT , El-Azhary RA , Patzelt MT , et al. Survival, risk factors, and effect of treatment in 101 patients with calciphylaxis. Mayo Clin Proc. 2016;91(10):1384-1394. doi:10.1016/j.mayocp.2016.06.025 PubMed Google Scholar Crossref

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 credit toward the CME [and Self-Assessment requirements] of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.